Skip to content

mHealth Intervention Supporting HIV Treatment Adherence and Retention

mHealth Intervention Supporting HIV Treatment Adherence and Retention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01951092
Enrollment
32
Registered
2013-09-26
Start date
2013-02-28
Completion date
2014-06-30
Last updated
2016-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, HIV, Retention

Keywords

HIV, adherence, retention, texting

Brief summary

Despite advances in antiretroviral treatment (ART) over the past 10 years, the incidence of HIV in the United States remains stagnant with over 50,000 new cases annually. HIV-infected individuals inconsistently engaged with care are less likely to receive ART which is associated with correspondingly adverse clinical outcomes in the long term and increased risk of transmission. Mobile health (mHealth) strategies including cell phone and text messaging have shown success in the developing world for medication adherence, yet mHealth interventions have not been developed to improve retention in HIV care. This strategy needs to be tested to demonstrate feasibility, acceptability and preliminary effectiveness in supporting HIV treatment adherence in Rhode Island. The Miriam Hospital Immunology Center is an urban HIV-clinic that provides comprehensive primary and specialty care for over 1400 HIV-infected patients. It is the largest HIV clinic in Rhode Island with patients also referred from eastern Connecticut and southern Massachusetts. In 2010, there were 165 new patients in clinic, 70 of whom were diagnosed within 1 year of entering care. In this environment, we propose a pilot study with the following specific aims: Specific Aim 1: To pilot a bidirectional mHealth intervention among individuals at high risk of loss to follow-up, including those with a recent HIV diagnosis or those re-engaging in HIV care. HIV-infected persons (n=30) with a recent diagnosis or re-engaging in care at the Immunology Center at TMH will be recruited to participate in a bidirectional mHealth intervention that delivers automated, regularly scheduled appointment and medication adherence reminders in an individualized format, and also allows individuals to request motivational enhancement and problem-solving support to address barriers to care. Specific Aim 2: To assess the impact and acceptability of the pilot intervention through qualitative interviews. All participants will also be invited to complete individual in-depth interviews which will assess acceptability and effectiveness of the pilot mHealth intervention, such as content and frequency of automatic messages, for retention and medication adherence for HIV-infected individuals in RI. The results of this study will provide preliminary data to inform an R21 or R34 application to determine efficacy of an mHealth intervention among HIV-infected persons at high-risk for loss to follow-up.

Interventions

OTHERText messaging

Sponsors

The Miriam Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV infected * age \>/= 18 * patient at The Miriam Hospital Immunology Center * has cell phone that can send and receive text messages * English speaking only

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Number of Particpatns Who Considered the Intervention Feasible and Acceptable6 monthsA qualitative interview is completed at the end of the 6 month intervention where participants are queried on aspects of the texting intervention including: frequency of messaging, content of messaging, comfort with confidentiality with messaging, interactions between clinic staff as a result of messaging, and ideas on how to incorporate messaging clinic-wide.

Secondary

MeasureTime frameDescription
Efficacy6 monthsExploratory end point of PVL \<200 copies at the end of the study

Countries

United States

Participant flow

Recruitment details

Patients at the Immunology Center in Providence RI who were either 1) newly diagnosed, 2) returning to care after a gap, 3) or with difficulties with adherence to care were eligible for enrollment in this pilot study. Participants were recruited from January 2013 through July 2013 and followed for 6 months.

Participants by arm

ArmCount
Single Arm Intervention Study
All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
32
Total32

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyIncarceration1
Overall StudyLost to Follow-up10
Overall StudyTransfer of Care1

Baseline characteristics

CharacteristicSingle Arm Intervention Study
Age, Continuous36 years
Participants with HIV PVL <200 copies/mL18 participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
20 Participants
Region of Enrollment
United States
32 participants
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
22 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 32
serious
Total, serious adverse events
0 / 32

Outcome results

Primary

Number of Particpatns Who Considered the Intervention Feasible and Acceptable

A qualitative interview is completed at the end of the 6 month intervention where participants are queried on aspects of the texting intervention including: frequency of messaging, content of messaging, comfort with confidentiality with messaging, interactions between clinic staff as a result of messaging, and ideas on how to incorporate messaging clinic-wide.

Time frame: 6 months

Population: All 20 participants who completed the study at 6 months participated in interviews and reported that the texting intervention was feasible and acceptable.

ArmMeasureValue (NUMBER)
Single Arm Intervention StudyNumber of Particpatns Who Considered the Intervention Feasible and Acceptable20 participants
Secondary

Efficacy

Exploratory end point of PVL \<200 copies at the end of the study

Time frame: 6 months

ArmMeasureValue (NUMBER)
Single Arm Intervention StudyEfficacy32 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026